Latest From Ipsen
This week's company moves include the sudden departure of Celgene's COO, new CEOs at Abeona Therapeutics, Kleo Pharmaceuticals and Corvidia Therapeutics, while board appointments have been made at Neurocentrx, Hemogenyx Pharmaceuticals, Emergex Vaccines and Rezolute Inc.
Ipsen's chief medical officer Sotirios Stergiopoulos talks about the company's R&D and licensing strategy that he hopes will push Ipsen's oncology unit to the next level.
Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.
The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.
- OTC, Consumer
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Beaufour Ipsen
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Senior Management
David Meek, CEO
Claude Bertrand, PhD, EVP, R&D & CSO
Aymeric Le Chatelier, EVP, Fin.
Ivana Magovcevic-Liebisch, EVP, CBO
Benoit Hennion, EVP, Pres., Primary Care
- Contact Info
Phone: (33) 1 58 33 50 00
65 quai George Gorse
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.